225Ac-RYZ-811

N/A

Report date: 2026/04/23 20:00:25

NME

Base Information

Drug Name225Ac-RYZ-811

Drug Alias Name225Ac-RYZ-811

ClassificationRadiation-emitting products > Nuclides > Actinium > 225AcRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Radionuclide Drug Conjugates +[5]

Mechanisms of ActionGlypican-3 binders

TargetsGlypican-3

Therapy Area/IndicationsCarcinoma, Hepatocellular

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryJapan

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesPeptiDream Inc

China Registration ClassN/A

Develop Information

Active CompaniesPeptiDream Inc

Inactive CompaniesN/A

Active IndicationsCarcinoma, Hepatocellular

Inactive IndicationsN/A

Other Information

ATC CodeN/A